Influence of glycosylation on the development and treatment of neuroblastoma.

Neuroblastoma is a solid malignancy observed in pediatric patients that develops when neuroblasts are unable to mature, leading to unregulated proliferation and tumor formation. Neuroblastoma commonly manifests in the adrenal gland, but may also form in the neck, chest, or spinal cord. Neuroblastoma is heterogeneous and aggressive in nature, leading to high treatment failure, morbidity, and mortality rates. Lewis family glycans, as part of the Core 2 O- glycans, play a key role in neuroblastoma malignant cell behavior in MYCN-amplified cell lines. Current treatment approaches for neuroblastoma include chemotherapy, surgery, and radiation. These approaches are faced with physiological and cellular barriers, including the influence of glycosylation in cancer diseases. Studies have confirmed that the inhibition of mucin glycosylation has improved effectiveness of cytotoxic drug agents employed against solid malignancies such as with pancreatic cancer, yet little research is available regarding the influence of glycosylated proteins for other diseases. This article reviews the effect of glycosylation on the development and treatment of neuroblastoma.

神经母细胞瘤是一种在儿科患者中观察到的实体恶性肿瘤，当神经母细胞无法成熟时就会发生，导致不受调控的增殖和肿瘤形成。神经母细胞瘤通常出现在肾上腺，但也可能在颈部、胸部或脊髓形成。神经母细胞瘤本质上具有异质性和侵袭性，导致治疗失败率、发病率和死亡率较高。路易斯家族聚糖作为核心2 - O -聚糖的一部分，在MYCN扩增的细胞系中对神经母细胞瘤恶性细胞行为起着关键作用。目前神经母细胞瘤的治疗方法包括化疗、手术和放疗。这些方法面临生理和细胞障碍，包括糖基化在癌症疾病中的影响。研究已证实，抑制粘蛋白糖基化提高了针对实体恶性肿瘤（如胰腺癌）使用的细胞毒性药物的有效性，但关于糖基化蛋白对其他疾病的影响的研究很少。本文综述了糖基化对神经母细胞瘤发展和治疗的影响。